Cure8 news brief
Early-phase data suggest PALI-2108 reaches the ileum and colon and produced rapid reductions in endoscopic inflammation and fecal calprotectin in small Phase 1b cohorts—results that could matter if confirmed in larger trials for people with Crohn’s disease or UC.
Adults with Crohn’s disease (including fibrostenotic disease), adults with ulcerative colitis, patients on biologic therapy, IBD clinicians, and researchers focused on oral small-molecule therapies and fibrosis/biomarker development.
Palisade Bio presented Phase 1b translational and early clinical data for PALI-2108 (active metabolite PALI-0008) at UEG Week 2026.
In a five-patient Crohn’s disease cohort with fibrostenotic ileal disease, investigators reported a mean 47.5% reduction in endoscopic disease activity after 14 days and a 58.8% mean decrease in fecal calprotectin; tissue analyses showed increased ileal cAMP (PDE4 target engagement) and reductions in inflammatory-cell populations.
The company is enrolling a Phase 2b study in UC and initiating a Phase 2a study in Crohn’s disease. These findings are exploratory, from small cohorts, and do not establish efficacy or antifibrotic benefit.
These are Phase 1b, small open-label cohorts (five patients per cohort reported here); findings are exploratory and hypothesis-generating. One observation of a previously non-traversable stricture becoming traversable is a single-patient result and does not prove reversal of fibrosis. Safety and efficacy must be confirmed in larger, controlled trials.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
Early Phase 1 findings suggest a gut-targeted PDE4 prodrug may engage its target in diseased tissue and produce early improvements in symptoms, endoscopy, and tissue inflammation — findings that, if confirmed in Phase 2,...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
